Release time：Jan 04, 2024
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, today announced the company has entered into a licensing and commercialization agreement with an Indonesian pharmaceutical company for it’s MAILISHU (a biosimilar of Prolia?). Under the terms of the Agreement, the partner has the exclusive rights to register, import, market and sell MAILISHU in Indonesia.
MAILISHU has been approved by the China National Medical Products Administration (NMPA) in March 2023. The partner is responsible for submitting the marketing application for MAILISHU in Indonesia. Previously, Mabwell had granted the exclusive sales rights of JUNMAIKANG (Adalimumab solution for injection, a biosimilar of HUMIRA?) to the partner for Indonesia market.
Mr. Huiguo Hu, Board member and Senior Vice President of Mabwell, said: “Mabwell is pleased to the establishment of collaboration in Indonesia for MAILISHU. Indonesia is the key market in South East Asian territory with about 275 million population. The local partner has strong registration and commercialization capabilities of biological products. This new agreement following the cooperation of JUNMAIKANG represents the full recognition of our product quality and high standard of clinical data of our products. It will strengthen Mabwell’s presence in one of the promising markets in the ASEAN markets and benefit the patients in Indonesia by providing high quality affordable biological medicines.”
